ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care. 2023;46:S19-40.

Article  CAS  PubMed  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6. Glycemic targets: standards of care in diabetes-2023. Diabetes Care. 2023;46:S97-110.

Article  PubMed  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46:S140-57.

Article  CAS  PubMed  Google Scholar 

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.

Article  CAS  PubMed  Google Scholar 

United Kingdom Prospective Diabetes Study (UKPDS). 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310(6972):83–8.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–65. https://doi.org/10.1016/S0140-6736(98)07037-8.

Monami M, Adalsteinsson JE, Desideri CM, Ragghianti B, Dicembrini I, Mannucci E. Fasting and post-prandial glucose and diabetic complication A meta-analysis. Nutr Metab Cardiovasc Dis. 2013;23:591–8.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Hu G, Yuan Z, Chen L. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE. 2012;7: e42551.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mannucci E, Monami M, Lamanna C, Adalsteinsson JE. Post-prandial glucose and diabetic complications: systematic review of observational studies. Acta Diabetol. 2012;49:307–14.

Article  CAS  PubMed  Google Scholar 

Kataoka Y, Yasuda S, Asaumi Y, Honda S, Noguchi T, Miyamoto Y, et al. Long-term effects of lowering postprandial glucose level on cardiovascular outcomes in early-stage diabetic patients with coronary artery disease: 10-year post-trial follow-up analysis of the DIANA study. J Diabetes Complications. 2023;37: 108469.

Article  CAS  PubMed  Google Scholar 

Wang Y, Yu L, Wang Y, Zhou J, Wu Y, Liu T, et al. Postload plasma glucose but not fasting plasma glucose had a greater predictive value for cardiovascular disease in a large prospective cohort study in southwest China. Front Cardiovasc Med. 2021;8: 815357.

Article  CAS  PubMed  Google Scholar 

Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia. 2001;44:929–45.

Article  CAS  PubMed  Google Scholar 

Del Prato S. Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia. 2003;46(Suppl 1):M2-8.

Article  PubMed  Google Scholar 

Bonora E, Corrao G, Bagnardi V, Ceriello A, Comaschi M, Montanari P, et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia. 2006;49:846–54.

Article  CAS  PubMed  Google Scholar 

DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397–405.

Nakagami T, Qiao Q, Tuomilehto J, Balkau B, Tajima N, Hu G, et al. Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil. 2006;13:555–61.

Article  PubMed  Google Scholar 

Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose The Funagata Diabetes Study. Diabetes Care. 1999;22:920–4.

Article  CAS  PubMed  Google Scholar 

Luc K, Schramm-Luc A, Guzik TJ, Mikolajczyk TP. Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol. 2019;70(6). https://doi.org/10.26402/jpp.2019.6.01.

Mah E, Bruno RS. Postprandial hyperglycemia on vascular endothelial function: mechanisms and consequences. Nutr Res. 2012;32:727–40.

Article  CAS  PubMed  Google Scholar 

Wu J, Xia S, Kalionis B, Wan W, Sun T. The role of oxidative stress and inflammation in cardiovascular aging. Biomed Res Int. 2014;2014: 615312.

Article  PubMed  PubMed Central  Google Scholar 

Ketema EB, Kibret KT. Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systematic review and meta-analysis. Arch Public Health. 2015;73:43.

Article  PubMed  PubMed Central  Google Scholar 

Zamani M, Nikbaf-Shandiz M, Aali Y, Rasaei N, Zarei M, Shiraseb F, et al. The effects of acarbose treatment on cardiovascular risk factors in impaired glucose tolerance and diabetic patients: a systematic review and dose–response meta-analysis of randomized clinical trials. Front Nutr. 2023;10:1084084.

Article  PubMed  PubMed Central  Google Scholar 

Zhang X-L, Yuan S-Y, Wan G, Yuan M-X, Yang G-R, Fu H-J, et al. The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24). Sci Rep. 2021;11:4839.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Esposito K, Giugliano D, Nappo F, Marfella R, Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110:214–9.

Article  CAS  PubMed  Google Scholar 

Sheu WH-H, Rosman A, Mithal A, Chung N, Lim YT, Deerochanawong C, et al. Addressing the burden of type 2 diabetes and cardiovascular disease through the management of postprandial hyperglycaemia: an Asian-Pacific perspective and expert recommendations. Diabetes Res Clin Pract. 2011;92:312–21.

Aravind S, Saboo B, Sadikot S, Shah SN, Makkar B, Kalra S, et al. Consensus statement on management of post-prandial hyperglycemia in clinical practice in India. J Assoc Physicians India. 2015;63:45–58.

PubMed  Google Scholar 

Miñambres I, Pérez A. Is there a justification for classifying GLP-1 receptor agonists as basal and prandial? Diabetol Metab Syndr. 2017;9:6.

Article  PubMed  PubMed Central  Google Scholar 

Becker RHA, Stechl J, Steinstraesser A, Golor G, Pellissier F. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects. Diabetes Metab Res Rev. 2015;31:610–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davidson JA, Stager W, Paranjape S, Berria R, Leiter LA. Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data. Clin Diabetes Endocrinol. 2020;6:2.

Article  PubMed  PubMed Central  Google Scholar 

Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008;294:E846-852.

Article  CAS  PubMed  Google Scholar 

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–30.

Article  CAS  PubMed  Google Scholar 

Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519–29.

Article  CAS  PubMed  Google Scholar 

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.

Article  CAS  PubMed  Google Scholar 

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57.

Article  CAS  PubMed  Google Scholar 

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–51.

Article  CAS  PubMed  Google Scholar 

Horton ES. Defining the role of basal and prandial insulin for optimal glycemic control. J Am Coll Cardiol. 2009;53:S21–7.

Article  CAS  PubMed  Google Scholar 

Hinnen DA. Therapeutic options for the management of postprandial glucose in patients with type 2 diabetes on basal insulin. Clin Diabetes. 2015;33:175–80.

Article  PubMed  PubMed Central